Abstracts tagged "Health Services Research"

Abstract Number: 1908 • ACR Convergence 2023
Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center
Kubra Bugdayli¹, Amber Meyer¹, Antoinette Keith¹, Karunakar Dirisala¹, Guillermo Quiceno¹ and Puneet Bajaj², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hypertension is the most common modifiable risk factor for cardiovascular diseases among all adults. Studies have shown that single blood pressure (BP) measurements vary…
Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Vibeke Strand¹, Prajakta Masurkar², Jennifer Reckleff³, Taylor Schwartz⁴, Alison Silverstein⁴, Jennifer Osborne⁴, Josie Lloyd⁴, Brian Leinwand⁴, Elaine Karis⁵, Fatima Barbar-Smiley⁶ and Karen Costenbader⁷, ¹Stanford University, Portola Valley, CA, ²Amgen, Inc., Atlanta, GA, ³Amgen, Inc., Westlake Village, CA, ⁴Inovalon Insights, Bowie, MD, ⁵Amgen, Inc., Colts Neck, NJ, ⁶Amgen, Inc., Dublin, OH, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
Abstract Number: 0997 • ACR Convergence 2023
Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
Abstract Number: 0172 • ACR Convergence 2023
Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review
Krystel Aouad¹, Maarten de Wit², Muriel Elhai³, Diego Benavent⁴, Heidi Bertheussen⁵, Jette Primdahl⁶, Codruta Zabalan⁷, Paul Studenic⁸ and Laure Gossec⁹, ¹Saint George Hospital University Medical Center, Beirut, Lebanon, ²Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ³University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁴Hospital la Paz, Madrid, Spain, ⁵Patient Research Partner, Oslo, Norway, ⁶University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ⁷Patient Research Partner, Romania, Romania, Romania, ⁸Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Patient research partners (PRPs) participate in research teams and provide unique and valuable input. Their integration as equal partners is recommended (1). However, PRP…
Abstract Number: 0998 • ACR Convergence 2023
Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
Rebecca Slotkin¹, Daniel Granda Calderón², Joselito Malca Hernandez², Diego Cabrera³, Carlos Manuel Benites Villafane⁴, Patricia Jannet García⁵ and Evelyn Hsieh⁶, ¹Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health, New Haven, CT, ²Facultad de Medicina Alberto Hurtado de la Universidad Peruana Cayetano Heredia, Lima, Peru, ³Yale University, Department of Medicine, Section of Rheumatology; Department of Internal Medicine, Waterbury Hospital, New Haven, CT, ⁴Ministerio de Salud, Peru, Lima, Peru, ⁵Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru, ⁶Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Persons living with HIV (PLWH) have a higher risk of developing age-related non-communicable diseases (NCDs), such as osteoporosis and sarcopenia. In Peru, HIV providers…
Abstract Number: 1656 • ACR Convergence 2023
Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)
anna Fryxelius¹, Amy Martinsen², Ida Løchting³, Linda Aimee Hartford Kvæl⁴, Astrid Lunestad², Astrid Bergland⁴ and Kjersti Storheim², ¹Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ⁴OsloMET, Oslo, Norway
Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
Abstract Number: 2023 • ACR Convergence 2023
Transition Readiness over Time in a Rheumatology Transition Clinic
Background/Purpose: In 2018 we designed a Rheumatology Transition clinic to care for adolescent patients with autoimmune disease. We incorporate Health Care Transition curriculum (HCT) into…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0999 • ACR Convergence 2023
Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Kranti Rumalla¹, Sumanth Chandrupatla² and Jasvinder Singh², ¹Northwestern School of Medicine, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Over 450,000 primary total hip arthroplasties (THA) are performed each year. One major indication for primary THA is the presence of osteoarthritis (OA). Patient…
Abstract Number: 1807 • ACR Convergence 2023
Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Most data on the effect of comorbidities on primary total hip arthroplasty (THA) outcomes is focused on conditions that directly impact joint health, or…
Abstract Number: 2046 • ACR Convergence 2023
Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic
Elizabeth Murray¹, Melissa Argraves¹, Alysha Taxter², Kelly Wise³, Paul Jensen⁴, Alana Goldstein-Leever¹, Bethanne Thomas¹, Alexa Scott¹, Jonnie Lee Hughes¹, James Gallup¹, Diana Sumano Vicente¹, Stacy Ardoin¹ and Vidya Sivaraman¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's, Columbus, OH, ³Nationwide Children's Hospital, Hilliard, OH, ⁴Intermountain Southwest Rheumatology Associates, St. George, UT
Background/Purpose: Many pediatric patients are inadequately prepared for the transition from pediatric to adult subspecialty healthcare, and patients who fail to transition successfully are more…
Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Jessica Ellis¹, Anita McGrogan², Neil McHugh², Ben Mulhearn³, Eleanor Korendowych⁴, John Pauling⁵, Ian Bruce⁶, Jenny Humphreys⁷ and Sarah Skeoch¹, ¹University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Bath, Bath, United Kingdom, ³Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Manchester, Stockport, United Kingdom
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…
Abstract Number: 0176 • ACR Convergence 2023
Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Social determinants of health (SDOH) have a significant impact on the health outcomes of many chronic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].